Glucosaminesulfaat remt osteoarthritis aan de knie.
Uit een driejarig,dubbelblinden placebo, onderzoek blijkt dat glucosaminesulfaat osteoarthritis doet
afremmen en mogelijk zelfs kan verminderen.
Background Conventional
symptomatic treatments for osteoarthritis do not favorably affect disease
progression. The aim of this randomized, placebo-controlled trial was to
determine whether long-term (3-year) treatment with glucosamine sulfate can
modify the progression of joint structure and symptom changes in knee
osteoarthritis, as previously suggested. Methods Two
hundred two patients with knee osteoarthritis (using American College of
Rheumatology criteria) were randomized to receive oral glucosamine sulfate, 1500
mg once a day, or placebo. Changes in radiographic minimum joint space width
were measured in the medial compartment of the tibiofemoral joint, and symptoms
were assessed using the algo-functional indexes of Lequesne and WOMAC (Western
Ontario and McMaster Universities). Results Osteoarthritis
was of mild to moderate severity at enrollment, with average joint space widths
of slightly less than 4 mm and a Lequesne index score of less than 9 points.
Progressive joint space narrowing with placebo use was -0.19 mm (95% confidence
interval, -0.29 to -0.09 mm) after 3 years. Conversely, there was no average
change with glucosamine sulfate use (0.04 mm; 95% confidence interval, -0.06 to
0.14 mm), with a significant difference between groups (P = .001). Fewer
patients treated with glucosamine sulfate experienced predefined severe
narrowings (>0.5 mm): 5% vs 14% (P = .05). Symptoms improved modestly
with placebo use but as much as 20% to 25% with glucosamine sulfate use, with
significant final differences on the Lequesne index and the WOMAC total index
and pain, function, and stiffness subscales. Safety was good and without
differences between groups. Conclusion Long-term
treatment with glucosamine sulfate retarded the progression of knee
osteoarthritis, possibly determining disease modification. Arch Intern Med.
2002;162:2113-2123
